Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - vorikonazol - aspergillosis; candidiasis; mycoses - antimycotics za sistemsko uporabo, triazol derivati - voriconazole je v širokem spektru, triazol protiglivično sredstvo, ter je označena pri odraslih in otrocih, starih dve leti ali več, kot sledi:zdravljenje invazivne aspergillosis;zdravljenje candidaemia v ne-neutropenic bolnikov;zdravljenje fluconazole-odporne resno invazivne candida okužbe (vključno c. krusei);zdravljenje hude glivične okužbe, ki jih povzročajo scedosporium spp. in oxysporum spp. voriconazole soglasju mora biti urejen, predvsem pri bolnikih z napredujočo, morda celo smrtno nevarne okužbe.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - topotekan - koncentrat za raztopino za infundiranje - topotekan 1 mg / 1 ml - topotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - multiple skleroza - druga zdravila na živčnem sistemu - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - ondansetron - raztopina za injiciranje/infundiranje - ondansetron 2 mg / 1 ml - ondansetron